{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T11:50:07Z","timestamp":1791805807484,"version":"4.3.4"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lipoprotein(a) [Lp(a)] is a causal risk factor for atherosclerotic cardiovascular disease, which remains unaddressed by current lipid-lowering therapies. Given its established role as a genetic independent cardiovascular risk factor, national and international guidelines recommend screening for Lp(a) levels, as elevated concentrations indicate a higher risk of cardiovascular events. Despite these implications and the availability of a simple standardized assay reimbursed by the Italian National Health Service, Lp(a) testing remains largely underused in the Italian clinical practice. The aim of this project was to identify barriers to Lp(a) testing in clinical practice and to develop targeted strategies to promote its incorporation into secondary cardiovascular prevention strategies in Italy, using an implementation science framework.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This project adopted a multi-method approach, using the Behavior Change Wheel (BCW) framework to identify barriers to Lp(a) testing. Barriers identified in the literature were mapped using the Capability, Opportunity, Motivation\u2013 Behavior (COM-B) model, and further characterized through the Theoretical Domains Framework. Each identified barrier was subsequently discussed and rated for perceived impact during a multidisciplinary working group involving 12 stakeholders (cardiologists, internists, lipidologists and laboratory professionals). Building on these findings, several intervention strategies were developed in line with BCW guidance and prioritized by stakeholders during a second multidisciplinary working group to ensure overall feasibility\n                      <jats:bold>.<\/jats:bold>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Capability-related barriers, including limited knowledge of Lp(a) as a cardiovascular risk factor, and uncertainty about its role on patient management, were among the most influential. Opportunity barriers included the absence of approved Lp(a)-lowering treatments, and a lack of test standardization. Motivational barriers included a lack of evidence of clinical benefit of Lp(a) reduction and limited awareness of its role in patient management. To address the identified barriers, training initiatives, creation of working groups, sharing of practical tools, alignment between clinicians and laboratories, and patient support emerged as high-priority interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>To promote Lp(a) testing in secondary cardiovascular prevention Italian clinical practice, this project identified behavioral barriers across all COM-B domains and designed actionable key strategies using a theory-driven approach. Future research should pilot these activities to overcome identified barriers and improve patient management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1906713","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:44:18Z","timestamp":1788932658000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Identifying barriers to lipoprotein(a) testing in secondary cardiovascular prevention and co-designing implementation strategies: an Italian behavior change wheel-informed study"],"prefix":"10.3389","volume":"13","author":[{"given":"Marcello","family":"Arca","sequence":"first","affiliation":[{"name":"Department of Translational and Precision Medicine, Sapienza University of Rome","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Marcucci","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence","place":["Florence, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo Pietro","family":"Maggioni","sequence":"additional","affiliation":[{"name":"ANMCO Research Center-Heart Care Foundation","place":["Florence, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Bilato","sequence":"additional","affiliation":[{"name":"Division of Cardiology, West Vicenza General Hospitals","place":["Arzignano, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Stabile","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Health Sciences, Universit\u00e0 Della Basilicata","place":["Potenza, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cipollone","sequence":"additional","affiliation":[{"name":"Clinica Medica Unit, Department of Medicine and Aging Sciences, University of Chieti-Pescara","place":["Chieti, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Capodanno","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico \u201cG. Rodolico-San Marco\u201d, University of Catania","place":["Catania, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Liuzzo","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Sciences, Fondazione Policlinico Gemelli IRCCS","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"Varbella","sequence":"additional","affiliation":[{"name":"Interventional Cardiology Unit, San Luigi Gonzaga University Hospital","place":["Orbassano, Italy"]},{"name":"Infermi Hospital ASL TO3, Rivoli","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Guerra","sequence":"additional","affiliation":[{"name":"Cardiology and Arrhythmology Clinic, Department of Biomedical Sciences and Public Health, Marche Polytechnic University","place":["Ancona, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Carugo","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Community Health, University of Milan and Fondazione Ospedale Maggiore IRCCS Policlinico Di Milano","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diletta","family":"Valsecchi","sequence":"additional","affiliation":[{"name":"Novartis Farma S.p.A.","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Cangini","sequence":"additional","affiliation":[{"name":"Novartis Farma S.p.A.","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio Maria","family":"Ghiringhelli","sequence":"additional","affiliation":[{"name":"IQVIA Solutions Italy S.r.l","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Parretti","sequence":"additional","affiliation":[{"name":"IQVIA Solutions Italy S.r.l","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Donnaloja","sequence":"additional","affiliation":[{"name":"IQVIA Solutions Italy S.r.l","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberico Luigi","family":"Catapano","sequence":"additional","affiliation":[{"name":"Department of Pharmacological and Biomolecular Sciences, University of Milan, and IRCCS Multimedica","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(24)01308-4","article-title":"Lipoprotein(a) and cardiovascular disease","volume":"404","author":"Nordestgaard","year":"2024","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) [lipoprotein(a)] concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European atherosclerosis society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e1082","DOI":"10.1161\/CIR.0000000000000625","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.cjca.2021.03.016","article-title":"2021 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1016\/j.numecd.2023.07.019","article-title":"Consensus document on lipoprotein(a) from the Italian society for the study of atherosclerosis (SISA)","volume":"33","author":"Chiesa","year":"2023","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e025397","DOI":"10.1161\/JAHA.121.025397","article-title":"Lipoprotein(a) and the risk for coronary heart disease and ischemic stroke events among black and white adults with cardiovascular disease","volume":"11","author":"Colantonio","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"B10","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1161\/ATVBAHA.119.312951","article-title":"Lipoprotein(a)-lowering by 50\u2005mg\/dL (105\u2005nmol\/L) may be needed to reduce cardiovascular disease 20% in secondary prevention: a population-based study","volume":"40","author":"Madsen","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"4762","DOI":"10.1093\/eurheartj\/ehaf297","article-title":"Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US family heart database","volume":"46","author":"MacDougall","year":"2025","journal-title":"Eur Heart J"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1571395","DOI":"10.3389\/fcvm.2025.1571395","article-title":"Lipoprotein(a) as an early marker of cardiovascular events in high-risk subjects: insights from the moli-sani cohort study","volume":"12","author":"Gianfagna","year":"2025","journal-title":"Front Cardiovasc Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"119218","DOI":"10.1016\/j.atherosclerosis.2025.119218","article-title":"The Brussels international declaration on lipoprotein(a). Testing and Management","volume":"406","author":"Kronenberg","year":"2025","journal-title":"Atherosclerosis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"100350","DOI":"10.1016\/j.ahjo.2023.100350","article-title":"Lipoprotein(a): an important piece of the ASCVD risk factor puzzle across diverse populations","volume":"38","author":"Ciffone","year":"2024","journal-title":"Am Heart J Plus"},{"key":"B15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.56095\/eaj.v3i3.77","article-title":"Atherosclerotic cardiovascular disease and measurement of lipoprotein(a) levels in Italy","volume":"3","author":"Olmastroni","year":"2024","journal-title":"Eur J Atheroscler"},{"key":"B16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1748-5908-6-42","article-title":"The behaviour change wheel: a new method for characterising and designing behaviour change interventions","volume":"6","author":"Michie","year":"2011","journal-title":"Implement Sci"},{"key":"B17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13012-017-0605-9","article-title":"A guide to using the theoretical domains framework of behaviour change to investigate implementation problems","volume":"12","author":"Atkins","year":"2017","journal-title":"Implement Sci"},{"key":"B18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.33393\/grhta.2022.2391","article-title":"Opportunit\u00e0 cliniche e impatto sul sistema sanitario di un trattamento ottimale del paziente post-sindrome coronarica acuta","volume":"9","author":"Gargiulo","year":"2022","journal-title":"Glob Reg Health Technol Assess"},{"key":"B19","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1714\/2028.22042","article-title":"A novel standard protocol of long-term follow-up shared with general practitioners after percutaneous coronary intervention: appropriateness and economic impact","volume":"16","author":"Lettieri","year":"2015","journal-title":"G Ital Cardiol (Rome)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s12160-013-9486-6","article-title":"The behavior change technique taxonomy (v1) of 93 hierarchically clustered techniques: building an international consensus for the reporting of behavior change interventions","volume":"46","author":"Michie","year":"2013","journal-title":"Ann Behav Med"},{"key":"B21","volume-title":"The Behaviour Change Wheel: A Guide to Designing Interventions","author":"Michie","year":"2014"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e2611604","DOI":"10.17061\/phrp2611604","article-title":"A guide to scaling up population health interventions","volume":"26","author":"Milat","year":"2016","journal-title":"Public Health Res Pract"},{"key":"B23","doi-asserted-by":"publisher","first-page":"oeae064","DOI":"10.1093\/ehjopen\/oeae064","article-title":"Intra-individual variability in lipoprotein(a): the value of a repeat measure for reclassifying individuals at intermediate risk","volume":"4","author":"Harb","year":"2024","journal-title":"Eur Heart J Open"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e025907","DOI":"10.1136\/bmjopen-2018-025907","article-title":"Enhancing self-care adherence in patients with heart failure: a study protocol for developing a theory-based behaviour change intervention using the COM-B behaviour model (ACHIEVE study)","volume":"8","author":"Herber","year":"2018","journal-title":"BMJ Open"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1324544","DOI":"10.3389\/fdgth.2024.1324544","article-title":"Targeting behavioral factors with digital health and shared decision-making to promote cardiac rehabilitation-a narrative review","volume":"6","author":"Hoppchen","year":"2024","journal-title":"Front Digit Health"},{"key":"B26","doi-asserted-by":"publisher","first-page":"967887","DOI":"10.3389\/fmed.2022.967887","article-title":"Applying the behavior change wheel to design de-implementation strategies to reduce low-value statin prescription in primary prevention of cardiovascular disease in primary care","volume":"9","author":"Sanchez","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1016\/j.jacl.2025.04.010","article-title":"Promoting lipoprotein(a) awareness and testing for risk identification through outreach and teaching (PATRIOT-QI)","volume":"19","author":"Radfar","year":"2025","journal-title":"J Clin Lipidol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.pcad.2022.01.002","article-title":"Global think tank on the clinical considerations and management of lipoprotein(a): the top questions and answers regarding what clinicians need to know","volume":"73","author":"Virani","year":"2022","journal-title":"Prog Cardiovasc Dis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3390\/jcdd12050169","article-title":"Lipoprotein(a): assessing the current knowledge and gaps in screening and treatment-A","volume":"12","author":"Amaritei","year":"2025","journal-title":"Narrative Review. J Cardiovasc Dev Dis"},{"key":"B30","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.atherosclerosis.2022.02.013","article-title":"How should public health recommendations address lp(a) measurement, a causative risk factor for cardiovascular disease (CVD)?","volume":"349","author":"Catapano","year":"2022","journal-title":"Atherosclerosis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"100651","DOI":"10.1016\/j.ajpc.2024.100651","article-title":"High lipoprotein(a): actionable strategies for risk assessment and mitigation","volume":"18","author":"Reyes-Soffer","year":"2024","journal-title":"Am J Prev Cardiol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1161\/CIRCULATIONAHA.124.069210","article-title":"Lipoprotein(a) as a pharmacological target: premises, promises, and prospects","volume":"151","author":"Greco","year":"2025","journal-title":"Circulation"},{"key":"B33","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.atherosclerosis.2023.04.012","article-title":"Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European atherosclerosis society","volume":"374","author":"Kronenberg","year":"2023","journal-title":"Atherosclerosis"},{"key":"B34","doi-asserted-by":"publisher","first-page":"16","DOI":"10.33696\/cardiology.1.002","article-title":"Lipoprotein apheresis: first FDA indicated treatment for elevated lipoprotein(a)","volume":"1","author":"Nugent","year":"2020","journal-title":"Journal of Clinical Cardiology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwaf531","article-title":"Consideration of possible involvement of oxidation of lp(a) in the association between lp(a) and atrial fibrillation","author":"Kotani","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.amjcard.2020.03.043","article-title":"Lipoprotein (a): an update on a marker of residual risk and associated clinical manifestations","volume":"126","author":"Shah","year":"2020","journal-title":"Am J Cardiol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1194\/jlr.R061648","article-title":"Lipoprotein (a) measurements for clinical application","volume":"57","author":"Marcovina","year":"2016","journal-title":"J Lipid Res"},{"key":"B38","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1177\/0004563220968473","article-title":"Lp(a): when and how to measure it","volume":"58","author":"Cegla","year":"2021","journal-title":"Ann Clin Biochem"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1093\/eurjpc\/zwae276","article-title":"Lipoprotein(a): don't Forget about secondary prevention","volume":"31","author":"Bhatia","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"278","DOI":"10.23736\/S0393-0564.25.00077-9","article-title":"Lipoproteina(a) e rischio cardiovascolare: una roadmap per la gestione del paziente. Documento congiunto della societ\u00e0 italiana per lo studio dell'Aterosclerosi (SISA), della societ\u00e0 italiana di cardiologia (SIC), della associazione nazionale medici cardiologi ospedalieri (ANMCO) e di SIBioC","volume":"49","author":"Catapano","year":"2025","journal-title":"Biochim Clin"}],"updated-by":[{"DOI":"10.3389\/fcvm.2026.1995870","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000}}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1906713\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T11:24:27Z","timestamp":1791804267000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1906713\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":40,"alternative-id":["10.3389\/fcvm.2026.1906713"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1906713","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"article-number":"1906713"}}